Epigenetic biomarkers in colorectal cancer: premises and prospects

References

• Alonso, S., et al., 2015. Epigenetic inactivation of the extracellular matrix metallopeptidase ADAMTS19 gene and the metastatic spread in colorectal cancer. Clinical epigenetics, 7, 1–15.
   PubMed Web of Science ®Google Scholar
• Amatu, A., et al., 2013. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Clinical cancer research, 19, 2265–2272.
   PubMed Web of Science ®Google Scholar
• Amirghofran, Z., et al., 2008. Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: soluble forms in relation to tumor tissue expression and metastasis. Journal of gastrointestinal cancer, 39, 73–78.
   PubMedGoogle Scholar
• Barault, L., et al., 2015. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Annals of oncology, 26, 1994–1999.
   PubMed Web of Science ®Google Scholar
• Basati, G., et al., 2015. Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer. Tumor biology, 37, 1781–1788.
   PubMed Web of Science ®Google Scholar
• Baylin, S.B. and Jones, P.A., 2011. A decade of exploring the cancer epigenome – biological and translational implications. Nature reviews cancer, 11, 726–734.
   PubMed Web of Science ®Google Scholar
• Beggs, A.D., et al., 2015. Methylation changes in the TFAP2E promoter region are associated with BRAF mutation and poorer overall & disease free survival in colorectal cancer. Oncoscience, 2, 508.
   PubMedGoogle Scholar
• Benard, A., et al., 2014. Histone trimethylation at H3K4, H3K9 and H4K20 correlates with patient survival and tumor recurrence in early-stage colon cancer. BMC cancer, 14, 1.
   PubMed Web of Science ®Google Scholar
• Benard, A., et al., 2015. Nuclear expression of histone deacetylases and their histone modifications predicts clinical outcome in colorectal cancer. Histopathology, 66, 270–282.
   PubMed Web of Science ®Google Scholar
• Bird, A., 2002. DNA methylation patterns and epigenetic memory. Genes & development, 16, 6–21.
   PubMed Web of Science ®Google Scholar
• Brim, H., et al., 2014. An integrative CGH, MSI and candidate genes methylation analysis of colorectal tumors. PloS one, 9, e82185.
   PubMed Web of Science ®Google Scholar
• Calin, G.A., et al., 2002. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the national academy of sciences of the United States of America, 99, 15524–15529.
   PubMed Web of Science ®Google Scholar
• Calin, G.A., et al., 2004. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the national academy of sciences of the United States of America, 101, 2999–3004.
   PubMed Web of Science ®Google Scholar
• Carethers, J.M. and Jung, B.H., 2015. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology, 149, 1177–1190.
   PubMed Web of Science ®Google Scholar
• Chang, S.W., et al., 2015. miR-503 inhibits cell proliferation and induces apoptosis in colorectal cancer cells by targeting E2F3. International journal of clinical and experimental pathology, 8, 12853.
   PubMed Web of Science ®Google Scholar
• Chen, H., et al., 2016. Evaluation of Plasma miR-21 and miR-152 as diagnostic biomarkers for common types of human cancers. Journal of cancer, 7, 490.
   PubMed Web of Science ®Google Scholar
• Chen, Z., et al., 2015. miR-124 and miR-506 inhibit colorectal cancer progression by targeting DNMT3B and DNMT1. Oncotarget, 6, 38139–38150.
   PubMed Web of Science ®Google Scholar
• Chiadini, E., et al., 2015. EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab. Oncology letters, 9, 1432–1438.
   PubMed Web of Science ®Google Scholar
• Cleven, A.H., et al., 2014. CHFR Promoter Methylation Indicates Poor Prognosis in Stage II Microsatellite Stable Colorectal Cancer. Clinical cancer research, 20, 3261–3271.
   PubMed Web of Science ®Google Scholar
• Da Silva, T., et al., 2015. P-192DNA methylation profile of APC and DKK2 genes as biomarkers in colorectal cancer patients. Annals of oncology, 26, iv55–iv56.
   Web of Science ®Google Scholar
• Dunn, B.K., 2003. Hypomethylation: one side of a larger picture. Annals of the New York academy of sciences, 983, 28–42.
   PubMed Web of Science ®Google Scholar
• Ebert, M.P., et al., 2012. TFAP2E-DKK4 and chemoresistance in colorectal cancer. The New England journal of medicine, 366, 44–53.
   PubMed Web of Science ®Google Scholar
• Ebrahimi, F., et al., 2015. Deregulation of miR-126 expression in colorectal cancer pathogenesis and its clinical significance. Experimental cell research, 339, 333–341.
   PubMed Web of Science ®Google Scholar
• Esteller, M., 2007. Cancer epigenomics: DNA methylomes and histone-modification maps. Nature reviews genetics, 8, 286–298.
   PubMed Web of Science ®Google Scholar
• Esteller, M. and Herman, J.G., 2002. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. Journal of pathology, 196, 1–7.
   PubMed Web of Science ®Google Scholar
• Frühwald, M.C. and Plass, C., 2002. Global and gene-specific methylation patterns in cancer: aspects of tumor biology and clinical potential. Molecular genetics and metabolism, 75, 1–16.
   PubMed Web of Science ®Google Scholar
• Gao, X., et al., 2015a. Semaphorin-3F functions as a tumor suppressor in colorectal cancer due to regulation by DNA methylation. International journal of clinical and experimental pathology, 8, 12766.
   PubMed Web of Science ®Google Scholar
• Gao, Y., et al., 2015b. Down-regulation of miR-24-3p in colorectal cancer is associated with malignant behavior. Medical oncology, 32, 1–8.
   Web of Science ®Google Scholar
• Geramizadeh, B., 2015. Molecular biomarkers of colorectal cancer: a review of published articles from Iran. Annals of colorectal research, 3, e30100. doi: 10.17795.
   Google Scholar
• Gezer, U., et al., 2013. Characterization of H3K9me3-and H4K20me3-associated circulating nucleosomal DNA by high-throughput sequencing in colorectal cancer. Tumor biology, 34, 329–336.
   PubMed Web of Science ®Google Scholar
• Ghanbari, R., et al., 2015. Decreased expression of fecal miR-4478 and miR-1295b-3p in early-stage colorectal cancer. Cancer biomarkers, 15, 195–201.
   Web of Science ®Google Scholar
• Hu, Y., et al., 2015. Clinical significance of miR-1826 as a novel prognostic biomarker in colorectal cancer. Anti-cancer agents in medicinal chemistry, 16, 1109–1116.
   Web of Science ®Google Scholar
• Huang, L., et al., 2015. Hsa-miR-19a is associated with lymph metastasis and mediates the TNF-α induced epithelial-to-mesenchymal transition in colorectal cancer. Scientific reports, 25, 13350. doi: 10.1038/srep13350.
   Web of Science ®Google Scholar
• Hur, K., et al., 2014. Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut, 63, 635–646.
   PubMed Web of Science ®Google Scholar
• Ionov, Y., Matsui, S.I., and Cowell, J.K., 2004. A role for p300/CREB binding protein genes in promoting cancer progression in colon cancer cell lines with microsatellite instability. Proceedings of the national academy of sciences of the United States of America, 101, 1273–1278.
   PubMed Web of Science ®Google Scholar
• Juan, P., et al., 2015. Paired design study by real-time PCR: miR-378* and miR-145 are potent early diagnostic biomarkers of human colorectal cancer. BMC cancer, 15, 158.
   PubMed Web of Science ®Google Scholar
• Kai, Y., et al., 2015. Decreased miR-154 expression and its clinical significance in human colorectal cancer. World Journal of Surgical Oncology, 13, 1.
   PubMed Web of Science ®Google Scholar
• Lam, K., et al., 2016. DNA methylation based biomarkers in colorectal cancer: a systematic review. Biochimica et biophysica acta, 1866, 106–120.
   PubMed Web of Science ®Google Scholar
• Lee, D.W., et al., 2015. Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX. Clinical epigenetics, 7, 1–9.
   PubMed Web of Science ®Google Scholar
• Leszinski, G., et al., 2012. Relevance of histone marks H3K9me3 and H4K20me3 in cancer. Anticancer research, 32, 2199–2205.
   PubMed Web of Science ®Google Scholar
• Li, E., Beard, C., and Jaenisch, R., 1993. Role for DNA methylation in genomic imprinting. Nature, 366, 362–365.
   PubMed Web of Science ®Google Scholar
• Li, E., Bestor, T.H., and Jaenisch, R., 1992. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell, 69, 915–926.
   PubMed Web of Science ®Google Scholar
• Li, J., et al., 2016. Inhibition of miR-15b decreases cell migration and metastasis in colorectal cancer. Tumor biology, 37, 8765–8773.
   PubMed Web of Science ®Google Scholar
• Li, T., Gao, F., and Zhang, X.P., 2015. miR-203 enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer. Oncology reports, 33, 607–614.
   PubMed Web of Science ®Google Scholar
• Liu, M., et al., 2015a. Up-regulation of miR-592 correlates with tumor progression and poor prognosis in patients with colorectal cancer. Biomedicine & pharmacotherapy, 69, 214–220.
   PubMed Web of Science ®Google Scholar
• Liu, R.L., et al., 2015b. Tumor suppressor miR-145 reverses drug resistance by directly targeting DNA damage-related gene RAD18 in colorectal cancer. Tumor biology, 36, 5011–5019.
   PubMed Web of Science ®Google Scholar
• Liu, T.P., et al., 2016. Down-regulation of let-7a-5p predicts lymph node metastasis and prognosis in colorectal cancer: implications for chemotherapy. Surgical oncology, 25, 1–6. doi: 10.1016/j.suronc.2016.05.016.
   PubMed Web of Science ®Google Scholar
• Liu, Z., et al., 2015c. MiR-592 inhibited cell proliferation of human colorectal cancer cells by suppressing of CCND3 expression. International journal of clinical and experimental medicine, 8, 3490–3497.
   Web of Science ®Google Scholar
• Lv, L., et al., 2015. DNA methylation is involved in the aberrant expression of miR-133b in colorectal cancer cells. Oncology letters, 10, 907–912.
   PubMed Web of Science ®Google Scholar
• Ma, W., et al., 2016. miR-517a is an independent prognostic marker and contributes to cell migration and invasion in human colorectal cancer. Oncology letters, 11, 2583–2589.
   PubMed Web of Science ®Google Scholar
• Magnani, G., et al., 2015. Molecular features and methylation status in early onset (≤ 40 years) colorectal cancer: a population based, case-control study. Gastroenterology research and practice, 501, 132190.
   Google Scholar
• Matthaios, D., et al., 2016. Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer. Oncology letters, 12, 748–756.
   PubMed Web of Science ®Google Scholar
• Mei, Q., et al., 2015. Methylation-induced loss of miR-484 in microsatellite-unstable colorectal cancer promotes both viability and IL-8 production via CD137L. Journal of Pathology, 236, 165–174.
   PubMed Web of Science ®Google Scholar
• Meng, W.J., et al., 2015. MicroRNA expression profile reveals miR-17-92 and miR-143-145 cluster in synchronous colorectal cancer. Medicine, 94, e1297. doi: 10.1097/MD.0000000000001297.
   PubMed Web of Science ®Google Scholar
• Migheli, F. and Migliore, L., 2012. Epigenetics of colorectal cancer. Clinical genetics, 81, 312–318.
   PubMed Web of Science ®Google Scholar
• Mojarad, E.N., 2013. The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterology and hepatology from bed to bench, 6, 120.
   PubMedGoogle Scholar
• Mokarram, P., et al., 2015a. MGMT-B gene promoter hypermethylation in patients with inflammatory bowel disease – a novel finding. Asian pacific journal of cancer prevention, 16, 1945–1952.
   PubMedGoogle Scholar
• Mokarram, P., et al., 2015b. The methylation status of MGMT and SFRP2 genes in Iranian patients with polyps. Thrita, 4, e28601.
   Google Scholar
• Mokarram, P., et al., 2015c. Promoter methylation status of two novel human genes, UBE2Q1 and UBE2Q2, in colorectal cancer: a new finding in Iranian patients. Asian pacific jounal of cancer prevention, 16, 8247–8252.
   PubMedGoogle Scholar
• Mokarram, P., et al., 2013. Different patterns of DNA methylation of the two distinct O6-methylguanine-DNA methyltransferase (O6-MGMT) promoter regions in colorectal cancer. Molecular biology reports, 40, 3851–3857.
   PubMed Web of Science ®Google Scholar
• Moutinho, C., et al., 2014. Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. Journal of the national cancer institute, 106, djt322.
   PubMedGoogle Scholar
• Nagasaka, T., et al., 2003. Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases. Clinical cancer research, 9, 5306–5312.
   PubMed Web of Science ®Google Scholar
• Naghibalhossaini, F., et al., 2011. High frequency of genes’ promoter methylation, but lack of BRAF V600E mutation among Iranian colorectal cancer patients. Pathology and oncology research, 17, 819–825.
   PubMed Web of Science ®Google Scholar
• Naghibalhossaini, F., et al., 2012. Epigenetic and genetic analysis of WNT signaling pathway in sporadic colorectal cancer patients from Iran. Molecular biology reports, 39, 6171–6178.
   PubMed Web of Science ®Google Scholar
• Naini, M.A., et al., 2016. Sensitive and noninvasive detection of aberrant SFRP2 and MGMT-B methylation in Iranian patients with colon polyps. Asian pacific journal of cancer prevention, 17, 2185–2193.
   PubMedGoogle Scholar
• Ng, E.K., et al., 2009. Differential expression of microRNAs in plasma of colorectal cancer patients: a potential marker for colorectal cancer screening. Gut, 58, 1375–1381.
   PubMed Web of Science ®Google Scholar
• Ng, J.M.K. and Yu, J., 2015. Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer. International journal of molecular sciences, 16, 2472–2496.
   PubMed Web of Science ®Google Scholar
• Niculescu, L.S., Vladica, M., and Sima, A.V., 2010. Association of APOA5 and APOC3 gene polymorphisms with plasma apolipoprotein A5 level in patients with metabolic syndrome. Biochemical and biophysical research communications, 391, 587–591.
   PubMed Web of Science ®Google Scholar
• Noguchi, T., et al., 2016. miRNA-503 promotes tumor progression and is associated with early recurrence and poor prognosis in human colorectal cancer. Oncology, 90, 221–231.
   PubMed Web of Science ®Google Scholar
• Okugawa, Y., Grady, W.M., and Goel, A., 2015. Epigenetic alterations in colorectal cancer: emerging biomarkers. Gastroenterology, 149, 1204–1225. e12.
   PubMed Web of Science ®Google Scholar
• Özdağ, H., et al., 2002. Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumours. British journal of cancer, 87, 1162–1165.
   PubMed Web of Science ®Google Scholar
• Pancione, M., Remo, A., and Colantuoni, V., 2012. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Pathology research international, 2012, 1–11. doi: 10.1155/2012/509348.
   Google Scholar
• Pfütze, K., et al., 2015. Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy. Genomics, 106, 348–354.
   PubMed Web of Science ®Google Scholar
• Qu, L., et al., 2015. Downregulation of miR-518a-3p activates the NIK-dependent NF-κB pathway in colorectal cancer. International journal of molecular medicine, 35, 1266–1272.
   PubMed Web of Science ®Google Scholar
• Rapti, S.M., et al., 2016. High miR-96 levels in colorectal adenocarcinoma predict poor prognosis, particularly in patients without distant metastasis at the time of initial diagnosis. Tumor biology, 37, 11815–11824.
   PubMedGoogle Scholar
• Robertson, K.D. and Wolffe, A.P., 2000. DNA methylation in health and disease. Nature reviews genetics, 1, 11–9.
   PubMed Web of Science ®Google Scholar
• Salehi, R., et al., 2015. Methylation pattern of ALX4 gene promoter as a potential biomarker for blood-based early detection of colorectal cancer. Nature reviews genetics, 4, 252.
   Google Scholar
• Scartozzi, M., et al., 2011. Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. British journal of cancer, 104, 1786–1790.
   PubMed Web of Science ®Google Scholar
• Schetter, A.J., et al., 2008. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA, 299, 425–436.
   PubMed Web of Science ®Google Scholar
• Schnekenburger, M. and Diederich, M., 2012. Epigenetics offer new horizons for colorectal cancer prevention. Current colorectal cancer reports, 8, 66–81.
   PubMedGoogle Scholar
• Shapiro, B., et al., 1983. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer, 51, 2116–2120.
   PubMed Web of Science ®Google Scholar
• Sheng, L., et al., 2015. miR-612 negatively regulates colorectal cancer growth and metastasis by targeting AKT2. Cell death & disease, 6, e1808.
   PubMed Web of Science ®Google Scholar
• Singer-Sam, J. and Riggs, A.D., 1993. X chromosome inactivation and DNA methylation. DNA Methylation. Basel, Switzerland: Birkhäuser Verlag, 358–384.
   Google Scholar
• Soravia, C., Bapat, B., and Cohen, Z., 1997. Familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC): a review of clinical, genetic and therapeutic aspects. Schweiz med wochenschr, 127, 682–690.
   PubMedGoogle Scholar
• Stoffel, E.M. and Boland, C.R., 2015. Genetics and genetic testing in hereditary colorectal cancer. Gastroenterology, 149, 1191–1203.
   PubMed Web of Science ®Google Scholar
• Sun, J., et al., 2015. MiR-200 suppresses metastases of colorectal cancer through ZEB1. Tumor biology, 7, 1–7. doi: 10.1007/s13277-015-3822-3.
   Google Scholar
• Szmida, E., et al., 2015. Aberrant methylation of ERBB pathway genes in sporadic colorectal cancer. Journal of applied genetics, 56, 185–192.
   PubMed Web of Science ®Google Scholar
• Takahashi, M., et al., 2012. The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PloS one, 7, e46684.
   PubMed Web of Science ®Google Scholar
• Tamagawa, H., et al., 2013. Global histone modification of H3K27 correlates with the outcomes in patients with metachronous liver metastasis of colorectal cancer. European journal of surgical oncology, 39, 655–661.
   PubMed Web of Science ®Google Scholar
• To, K.K., Leung, W., and Ng, S.S., 2015. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. Experimental cell research, 338, 222–231.
   PubMed Web of Science ®Google Scholar
• Toiyama, Y., et al., 2013. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. Journal of the national cancer institute, 105, 849–859.
   PubMedGoogle Scholar
• Toyota, M., et al., 1999. CpG island methylator phenotype in colorectal cancer. Proceeding of the national academy of sciences of the United States of America, 96, 8681–8686.
   PubMed Web of Science ®Google Scholar
• Tsai, M.H., et al., 2015. DNA hypermethylation of SHISA3 in colorectal cancer: an independent predictor of poor prognosis. Annals of surgical oncology, 22, 1481–1489.
   PubMed Web of Science ®Google Scholar
• Vychytilova-Faltejskova, P., et al., 2015. MiR-215 is a tumor suppressor in colorectal cancer in vitro and in vivo. Cancer research, 75, 3116.
   Google Scholar
• Waddington, C.H., 2012. The epigenotype 1942. International journal of epidemiol, 41, 10–13.
   PubMed Web of Science ®Google Scholar
• Wang, C.G., et al., 2010. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World Journal of Gastroenterology, 16, 2421–2427.
   PubMed Web of Science ®Google Scholar
• Wang, Q., et al., 2016a. Serum microRNA-135a-5p as an auxiliary diagnostic biomarker for colorectal cancer. Annals of Clinical Biochemistry, 53. doi: 10.1177/0004563216638108.
   Google Scholar
• Wang, W., et al., 2016b. Circulating miR‐210 as a diagnostic and prognostic biomarker for colorectal cancer. European journal of cancer care, 25, 12448. doi: 10.1111/ecc.12448.
   Google Scholar
• Wang, X., et al., 2015. Evaluation of miR-720 prognostic significance in patients with colorectal cancer. Tumour biology, 36, 719–727.
   PubMed Web of Science ®Google Scholar
• Weichert, W., et al., 2008. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clinical cancer research, 14, 1669–1677.
   PubMed Web of Science ®Google Scholar
• Weirich, C.S., Erzberger, J.P., and Barral, Y., 2008. The septin family of GTPases: architecture and dynamics. Nature reviews molecular cell biology, 9, 478–489.
   PubMed Web of Science ®Google Scholar
• Wu, C.W., et al., 2011. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut, 2011, 239236.
   Google Scholar
• Xia, J., Guo, X., and Deng, K., 2014. Epigenetics, microRNAs and human cancer. MicroRNAs: key regulators of oncogenesis. Switzerland: Springer International Publishing, 29–57.
   Google Scholar
• Xu, X.H., et al., 2015. Clinical value of serum miR-490-5p as a marker for early diagnosis of colorectal cancer. Tumor, 35, 1245–1250.
   Google Scholar
• Yang, F., et al., 2015. miR-143 regulates proliferation and apoptosis of colorectal cancer cells and exhibits altered expression in colorectal cancer tissue. International journal of clinical and experimental medicine, 8, 15308.
   PubMed Web of Science ®Google Scholar
• Yau, T.O., et al., 2016. MicroRNA-20a in human faeces as a non-invasive biomarker for colorectal cancer. Oncotarget, 7, 1559.
   PubMed Web of Science ®Google Scholar
• Ye, H., et al., 2015. A critical role of mir-199a in the cell biological behaviors of colorectal cancer. Diagnostic pathology, 10, 65.
   PubMed Web of Science ®Google Scholar
• Yu, J., et al., 2015. Serum miR-372 is a diagnostic and prognostic biomarker in patients with early colorectal cancer. Anti-cancer agents in medicinal chemistry, 16, 424–431.
   Web of Science ®Google Scholar
• Yuan, D., et al., 2015. Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer. Cancer biology & therapy, 16, 268–275.
   PubMed Web of Science ®Google Scholar
• Zhang, H., et al., 2015a. MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells. Cancer letters, 356, 781–790.
   PubMed Web of Science ®Google Scholar
• Zhang, X., et al., 2015b. Combined detection of plasma GATA5 and SFRP2 methylation is a valid noninvasive biomarker for colorectal cancer and adenomas. World journal of gastroenterology, 21, 2629.
   PubMed Web of Science ®Google Scholar
• Zhao, L.D., et al., 2016. Epigenetic silencing of miR-181b contributes to tumorigenicity in colorectal cancer by targeting RASSF1A. International journal of oncology, 48, 1977–1984.
   PubMed Web of Science ®Google Scholar
• Zheng, L., et al., 2015. MiR-106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer. Journal of translational medicine, 13, 252.
   PubMed Web of Science ®Google Scholar
• Zhu, M., et al., 2015. Regulation of UHRF1 by miR‐9 modulates colorectal cancer cell proliferation and apoptosis. Cancer science, 106, 833–839.
   PubMed Web of Science ®Google Scholar